[A randomized controlled study of adjuvant immunotherapy with N-CWS for head and neck malignancies].
The nonspecific adjuvant immunotherapeutic effectiveness of the cell wall skeleton of Nocardia rubra (N-CWS) was studied in patients with head-and-neck malignancies. This study involved 390 patients seen from March 1980 to July 1982. The patients qualifying for statistical analysis were limited to 276 with squamous cell carcinoma without a vestige of tumor after four months of radical therapy. They were divided into two background-factors matched groups of 132 immunotherapy and 144 control patients. The overall two-year nonrecurrence rate was 70.4% for the immunotherapy group and 67.1% for the control. This difference, however, was amplified, when the patients' stages were limited to III and IV: 66.6% for the immunotherapy group and 55.3% for the control.
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D002473:Cell Wall; D003131:Combined Modality Therapy; D005260:Female; D006258:Head and Neck Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009615:Nocardia; D011897:Random Allocation
D000276:Adjuvants, Immunologic